TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31913135

Group type: EXPERIMENTAL
Intervention: Study duration of 5 days
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Study duration of 15 days
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Study duration of 27 days
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Notification level light
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Notification level moderate
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Overall study completion rates
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Statistically meaningful results from trials
Number of subjects: 640
Study: 31913732

Group type: EXPERIMENTAL
Intervention: Culprit lesion (CL) re-MI
Number of subjects: 108615

Group type: EXPERIMENTAL
Intervention: Nonculprit lesion (NCL) re-MI
Number of subjects: 108615

Group type: EXPERIMENTAL
Intervention: Indeterminate re-MIs
Number of subjects: 108615

Group type: EXPERIMENTAL
Intervention: Multivessel disease
Number of subjects: 108615

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 108615

Group type: EXPERIMENTAL
Intervention: Prolonged time between index and re-MI
Number of subjects: 108615
Study: 31914032

Group type: EXPERIMENTAL
Intervention: Trimodal anastomosis testing (testing for blood supply by ICG fluorescence, mechanical integrity by air-leak and methylene blue leak tests, and tension testing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimodal anastomosis testing
Number of subjects: 0
Study: 31914871

Group type: EXPERIMENTAL
Intervention: smart instrumented splint
Number of subjects: 0
Study: 31914936

Group type: EXPERIMENTAL
Intervention: iSupport online program for three months
Number of subjects: 184

Group type: COMPARATOR
Intervention: Education-only e-book (comparison group)
Number of subjects: 184
Study: 31914997

Group type: EXPERIMENTAL
Intervention: COPE intervention (home-based outreach by Community Health Representatives)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: COPE intervention (health education delivered by CHRs)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: COPE intervention (education for family members by CHRs)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: COPE intervention (support for patients unable to see a primary care doctor)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: COPE intervention (trusting client-CHR relationships)
Number of subjects: 7
Study: 31915000

Group type: EXPERIMENTAL
Intervention: ACP+ programme (a multicomponent programme delivered stepwise over an eight-month period with the help of an external trainer)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ACP+ programme
Number of subjects: 14

Group type: COMPARATOR
Intervention: Care and education as usual
Number of subjects: 14
Study: 31915028

Group type: EXPERIMENTAL
Intervention: HIPK2 gene variant (rs2030712)
Number of subjects: 169
Study: 31915030

Group type: EXPERIMENTAL
Intervention: Ultrasonography using a stabilizing device
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combined ECUS and transit-time flow measurement (TTFM)
Number of subjects: 51
Study: 31915151

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (sleeve gastrectomy or sleeve gastrectomy and biliopancreatic diversion with duodenal switch)
Number of subjects: 12
Study: 31915159

Group type: EXPERIMENTAL
Intervention: Gut microbiota composition and body composition profile (obesity, sarcopenia, metabolic syndrome)
Number of subjects: 300
Study: 31915166

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombectomy (IAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra-arterial thrombectomy (IAT) with intravenous thrombolysis (IVT) at the nearest primary stroke centre (PSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Centralised care at a comprehensive stroke centre (CSC)
Number of subjects: 0
Study: 31915192

Group type: EXPERIMENTAL
Intervention: Gentamicin exposure (6 mg/kg)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 219
Study: 31915195

Group type: EXPERIMENTAL
Intervention: Acalabrutinib plus Obinutuzumab
Number of subjects: 45
Study: 31915837

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Global SBT LUS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anterolateral SBT LUS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Echocardiographic indices of filling pressures
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anterolateral LUS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Global and anterolateral SBT LUS
Number of subjects: 40
Study: 31916132

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 40
Study: 31916270

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 361
Study: 31916448

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 31916464

Group type: EXPERIMENTAL
Intervention: Intraoperative lung ultrasonography via thoracoscopy
Number of subjects: 89

Group type: COMPARATOR
Intervention: Manual exploration of the organ by thoracotomy
Number of subjects: 89
Study: 31916575

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 25-g dose
Number of subjects: 0
Study: 31916827

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) and light physical activity measured using Actigraph GT3X+ accelerometers
Number of subjects: 130
Study: 31916865

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31917194

Group type: EXPERIMENTAL
Intervention: Cognitive functioning (measured by Frontal Assessment Battery test)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10-Meter Walk Test (10MWT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Timed Up and Go (TUG) test
Number of subjects: 40
Study: 31917319

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31917843

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks for up to 8 cycles, starting within 21 days of post-ASCT discharge)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 29
Study: 31918324

Group type: EXPERIMENTAL
Intervention: NIU model
Number of subjects: 29010

Group type: EXPERIMENTAL
Intervention: NIU model refitted to EPI data
Number of subjects: 29010

Group type: EXPERIMENTAL
Intervention: NIU model for prediction of HER2-positivity in EPI
Number of subjects: 29010

Group type: EXPERIMENTAL
Intervention: NIU model fitted to NIU data
Number of subjects: 29010

Group type: EXPERIMENTAL
Intervention: Model with improved variables (progesterone and oestrogen receptor expression, method of sample extraction)
Number of subjects: 29010
Study: 31918531

Group type: EXPERIMENTAL
Intervention: Energy Conservation plus Problem-Solving Therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Health Education
Number of subjects: 23
Study: 31918944

Group type: EXPERIMENTAL
Intervention: IVUS-guided everolimus-eluting stent implantation
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Angiography-guided everolimus-eluting stent implantation
Number of subjects: 1400
Study: 31919012

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no milrinone)
Number of subjects: 26
Study: 31919092

Group type: EXPERIMENTAL
Intervention: Inhibitor development in patients with SHB
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Allergic reactions in inhibitor patients
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Genotype association with inhibitors
Number of subjects: 154
Study: 31919132

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus albumin-bound paclitaxel (ABP)
Number of subjects: 37
Study: 31919278

Group type: EXPERIMENTAL
Intervention: Tick-borne encephalitis (TBE) vaccination
Number of subjects: 20
Study: 31919404

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX every 2 weeks (adapted dose in stage two)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 30
Study: 31919663

Group type: EXPERIMENTAL
Intervention: Ophthalmological disorders present
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Monocular visual acuity (VA) testing not achieved
Number of subjects: 51
Study: 31920324

Group type: EXPERIMENTAL
Intervention: Multidisciplinary and person-centered care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study: 31920571

Group type: EXPERIMENTAL
Intervention: KINVIS therapy combined with conventional therapeutic exercise (TherEX) for 10 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: KINVIS therapy combined with conventional therapeutic exercise (TherEX)
Number of subjects: 11
Study: 31920716

Group type: EXPERIMENTAL
Intervention: Computational modeling-guided ablation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Empirical ablation
Number of subjects: 118
Study: 31920733

Group type: EXPERIMENTAL
Intervention: Lanicemine, NMDA receptor antagonist, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, specific details not available
Number of subjects: 0
Study: 31921371

Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Interval Aerobic Training (IAT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 52
Study: 31921432

Group type: EXPERIMENTAL
Intervention: SSPGA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LFA-REAL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SSPGA and LFA-REAL
Number of subjects: 50
Study: 31921443

Group type: EXPERIMENTAL
Intervention: Patient involvement in research team
Number of subjects: 380

Group type: COMPARATOR
Intervention: Previous study without patient involvement
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Researchers' attitudes towards patient involvement
Number of subjects: 380
Study: 31921715

Group type: EXPERIMENTAL
Intervention: Fluid strategy intervention, details not available
Number of subjects: 0
Study: 31922043

Group type: EXPERIMENTAL
Intervention: Simulation-based training program including directed self-regulated learning and post-testing
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional simulation-based training program
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both training programs
Number of subjects: 32
Study: 31922084

Group type: EXPERIMENTAL
Intervention: SC + Enhanced Program (SC + EP; 8 skill-building cores, monthly support sessions, targeted diet/physical activity strategies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care (SC; American Academy of Pediatrics overweight/obesity recommendations)
Number of subjects: 0
Study: 31922277

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa (AN)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Disease remission in anorexia nervosa (AN)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Other specified feeding or eating disorders (OSFED)
Number of subjects: 803
Study: 31922545

Group type: EXPERIMENTAL
Intervention: OAC with vitamin K antagonists
Number of subjects: 1405

Group type: EXPERIMENTAL
Intervention: OAC with vitamin K antagonists, clinically significant depressive symptoms (PHQ-2 ≥ 3)
Number of subjects: 1405
Study: 31923068

Group type: EXPERIMENTAL
Intervention: More acculturation (born in the United States with high English proficiency)
Number of subjects: 10006
Study: 31923098

Group type: EXPERIMENTAL
Intervention: Coronary revascularization (n=1617)
Number of subjects: 6085

Group type: COMPARATOR
Intervention: Medical therapy (n=1617)
Number of subjects: 6085

Group type: EXPERIMENTAL
Intervention: Coronary revascularization (n=2658)
Number of subjects: 6085

Group type: COMPARATOR
Intervention: Medical therapy (n=2658)
Number of subjects: 6085

Group type: EXPERIMENTAL
Intervention: Coronary revascularization (n=1810)
Number of subjects: 6085

Group type: COMPARATOR
Intervention: Medical therapy (n=1810)
Number of subjects: 6085
Study: 31923188

Group type: EXPERIMENTAL
Intervention: Non-mydriatic retinal photography
Number of subjects: 24
Study: 31923255

Group type: EXPERIMENTAL
Intervention: Telomere length (TL) and telomerase activity (TA) measured during index presentation with NSTEACS.
Number of subjects: 298
Study: 31923277

Group type: EXPERIMENTAL
Intervention: Radial basis neural networks
Number of subjects: 2940

Group type: EXPERIMENTAL
Intervention: Neural network models (product-unit, sigmoid unit, radial basis function)
Number of subjects: 2940
Study: 31923435

Group type: EXPERIMENTAL
Intervention: Firibrastat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renal artery denervation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baroreceptor device implantation
Number of subjects: 0
Study: 31923641

Group type: EXPERIMENTAL
Intervention: BLI-directed surveillance intervals
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Optical real-time analysis of diminutive rectosigmoid adenomas
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: BASIC classification accuracy
Number of subjects: 333
Study: 31923800

Group type: EXPERIMENTAL
Intervention: NGS matched therapy
Number of subjects: 506

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Overall therapeutic proposal
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Genetic susceptibility testing
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Matched treatment
Number of subjects: 506
Study: 31924241

Group type: EXPERIMENTAL
Intervention: Reparixin 1000 mg orally three times daily for 21 days before surgery
Number of subjects: 20
Study: 31924299

Group type: EXPERIMENTAL
Intervention: ER group (patients enrolled in TARGET-AC)
Number of subjects: 131

Group type: COMPARATOR
Intervention: NER group (patients not enrolled in TARGET-AC)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: ER group
Number of subjects: 131

Group type: COMPARATOR
Intervention: NER group
Number of subjects: 131
Study: 31924461

Group type: EXPERIMENTAL
Intervention: Eliglustat 84 mg single dose
Number of subjects: 14

Group type: COMPARATOR
Intervention: Matched healthy EM subjects (n=7)
Number of subjects: 14
Study: 31924681

Group type: EXPERIMENTAL
Intervention: Posttraumatic headaches (PTH+)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Nontraumatic headaches (PTH-)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Headaches in mTBI- group
Number of subjects: 557
Study: 31926552

Group type: EXPERIMENTAL
Intervention: Open carpal tunnel release
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pressure-strain ratio
Number of subjects: 45
Study: 31926561

Group type: EXPERIMENTAL
Intervention: FJS-12
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: WOMAC
Number of subjects: 120
Study: 31926776

Group type: EXPERIMENTAL
Intervention: Transgluteal approach
Number of subjects: 3018

Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 3018

Group type: COMPARATOR
Intervention: Anterior approach
Number of subjects: 3018

Group type: EXPERIMENTAL
Intervention: All approaches
Number of subjects: 3018
Study: 31927117

Group type: EXPERIMENTAL
Intervention: CABM patients
Number of subjects: 533
Study: 31927166

Group type: EXPERIMENTAL
Intervention: NLG207 (formerly CRLX101) nanoparticle-drug conjugate (NDC) of camptothecin (CPT)
Number of subjects: 0
Study: 31927479

Group type: EXPERIMENTAL
Intervention: Advanced care planning with three care intensities: intensive care, maximal medical care, and exclusive palliative care.
Number of subjects: 482
Study: 31927562

Group type: EXPERIMENTAL
Intervention: NVP/ZDV/3TC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LPV/r
Number of subjects: 40
Study: 31927670

Group type: EXPERIMENTAL
Intervention: Adherence to dietary recommendations (high adherence, 10th decile)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Western diet
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Healthy diet
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 160

Group type: COMPARATOR
Intervention: Consumption of vegetable added fat, sweetened food, milk and dairy products, and fruit and vegetable intakes
Number of subjects: 160
Study: 31928035

Group type: EXPERIMENTAL
Intervention: Rapport-building behaviors
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Gradual exposure through initial trauma-eliciting
Number of subjects: 65
Study: 31928294

Group type: EXPERIMENTAL
Intervention: Li81 (opicinumab)
Number of subjects: 0
Study: 31928530

Group type: EXPERIMENTAL
Intervention: C3 administration in GC cell lines
Number of subjects: 106

Group type: COMPARATOR
Intervention: C3 blocker pre-incubation
Number of subjects: 106

Group type: COMPARATOR
Intervention: JAK2 inhibitor pre-treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: High C3 deposition
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: C3 deposition correlation
Number of subjects: 106
Study: 31929102

Group type: EXPERIMENTAL
Intervention: Promotoras de Donación eLearning module
Number of subjects: 98
Study: 31929543

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting stents (PF-SES)
Number of subjects: 7243

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) regimens
Number of subjects: 7243
Study: 31929554

Group type: EXPERIMENTAL
Intervention: Performance-based financing free health care policy (PBF-FHC) including child nutrition services; duration from January 2015 to December 2016.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incentive and information tracks of the intervention; specific details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based recruitment strategy; specific details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management of inputs at the facility and patient level; specific details on dosage and duration not available.
Number of subjects: 0
Study: 31930057

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sertraline (75 mg/day)
Number of subjects: 21
Study: 31930095

Group type: EXPERIMENTAL
Intervention: Oral Chinese Medicine (CM) herbal medication administered twice daily for eight weeks.
Number of subjects: 1500

Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 1500
Study: 31930302

Group type: EXPERIMENTAL
Intervention: Hypertensive urgency (HypUrg) patients during follow-up (FU)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Hypertensive urgency (HypUrg) patients
Number of subjects: 469
Study: 31930374

Group type: EXPERIMENTAL
Intervention: Ambroxol therapy (1.26 g per day)
Number of subjects: 23
Study: 31930513

Group type: EXPERIMENTAL
Intervention: ERAS clinical pathway (CP)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Conventional clinical pathway (CP)
Number of subjects: 133
Study: 31931024

Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)-based active cellular immunotherapy using high hydrostatic pressure-killed cancer cells derived from NSCLC cell lines.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Presence of TAA-specific T cells in blood of NSCLC patients using commercially available peptide mixes in an in vitro stimulation assay.
Number of subjects: 32
Study: 31931768

Group type: EXPERIMENTAL
Intervention: Quantitative survey data collection in 2014, 2018, and 2021
Number of subjects: 3431

Group type: EXPERIMENTAL
Intervention: Qualitative data collection at five time points
Number of subjects: 3431

Group type: EXPERIMENTAL
Intervention: Workshops with intervention developers at Raising Voices
Number of subjects: 3431
Study: 31931767

Group type: EXPERIMENTAL
Intervention: Conventional medical care as determined by treating physicians
Number of subjects: 5000
Study: 31931776

Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC)
Number of subjects: 50
Study: 31931844

Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Number of subjects: 926

Group type: COMPARATOR
Intervention: Auscultation
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Agreement between lung ultrasound and auscultation
Number of subjects: 926

Group type: COMPARATOR
Intervention: Auscultation in non-ventilated patients
Number of subjects: 926
Study: 31931900

Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Water infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (Normal-weight women)
Number of subjects: 50
Study: 31932137

Group type: EXPERIMENTAL
Intervention: gp120-NefTat/AS01 vaccine
Number of subjects: 16
Study: 31932246

Group type: EXPERIMENTAL
Intervention: Breastfed HEU infants
Number of subjects: 869

Group type: COMPARATOR
Intervention: Breastfed HU infants
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Breastfed HEU infants with healthier mothers (n=84)
Number of subjects: 869
Study: 31932382

Group type: EXPERIMENTAL
Intervention: Linezolid treatment, specific dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31932458

Group type: EXPERIMENTAL
Intervention: p.V59M genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other genotypes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfonylurea treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebral MRI
Number of subjects: 0
Study: 31932515

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg oral tablets
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg subcutaneous monthly
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg subcutaneous monthly
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg oral tablets and Erenumab
Number of subjects: 2
Study: 31932960

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 411
Study: 31932999

Group type: EXPERIMENTAL
Intervention: Nordic walking training for 8 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Free walking training for 8 weeks
Number of subjects: 33
Study: 31933070

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 2235
Study: 31934472

Group type: EXPERIMENTAL
Intervention: Migalastat
Number of subjects: 1
Study: 31934592

Group type: EXPERIMENTAL
Intervention: Carotid atherosclerosis assessment by duplex ultrasonography
Number of subjects: 583

Group type: COMPARATOR
Intervention: Prior cardiovascular event
Number of subjects: 583